Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000905718-17-000603
Filing Date
2017-06-16
Accepted
2017-06-16 09:05:33
Documents
2
Period of Report
2017-06-15

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT cavanaugh_fm3jun152017.html 3  
1 OWNERSHIP DOCUMENT cavanaugh_fm3jun152017.xml 3 8387
2 POWER OF ATTORNEY cavanaugh_poa.htm EX-24 5203
  Complete submission text file 0000905718-17-000603.txt   15215
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Issuer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827
Business Address
Cavanaugh Sarah (Reporting) CIK: 0001709113 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-15006 | Film No.: 17914872